CRESCENT BIOPHARMA, INC. Increase (Decrease) in Deferred Revenue
CRESCENT BIOPHARMA, INC. (CBIO) reported Increase (Decrease) in Deferred Revenue of $0 for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-07-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2016-02-29
- CRESCENT BIOPHARMA, INC. increase (decrease) in deferred revenue for the quarter ending 2013-12-31 was -$77.41K.
- CRESCENT BIOPHARMA, INC. increase (decrease) in deferred revenue for the quarter ending 2013-09-30 was -$52.57K.
- CRESCENT BIOPHARMA, INC. increase (decrease) in deferred revenue for the quarter ending 2013-06-30 was -$55.07K.
- CRESCENT BIOPHARMA, INC. increase (decrease) in deferred revenue for the quarter ending 2013-03-31 was -$3.81M.
- CRESCENT BIOPHARMA, INC. increase (decrease) in deferred revenue for fiscal 2013 was -$3.99M.
- CRESCENT BIOPHARMA, INC. increase (decrease) in deferred revenue for fiscal 2012 was -$14.76M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2014-06-30 | $0.00 10-Q · filed 2014-07-31 | |||
| 2013-12-31 | -$77.41K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$129.98K derived: sum of 2 quarters · filed 2016-02-29 | -$185.06K derived: sum of 3 quarters · filed 2016-02-29 | -$3.99M 10-K · filed 2016-02-29 |
| 2013-09-30 | -$52.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$107.64K derived: sum of 2 quarters · filed 2014-10-31 | -$3.92M 10-Q · filed 2014-10-31 | |
| 2013-06-30 | -$55.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$3.86M 10-Q · filed 2014-07-31 | ||
| 2013-03-31 | -$3.81M 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | -$14.76M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |